{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:00:16Z","timestamp":1790622016363,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    This case describes the use of long\u2010acting injectable (LA\u2010I) cabotegravir\/rilpirivine (CAB\/RPV) therapy in a morbidly obese person (body mass index [BMI]\u2009=\u200962\u2009kg\u2009m\n                    <jats:sup>\u22122<\/jats:sup>\n                    ) living with HIV without sustained viral load (VL) suppression after historic poor adherence to daily oral antiretroviral therapy. Increased BMI\u2009&gt;\u200930\u2009kg\u2009m\n                    <jats:sup>\u22122<\/jats:sup>\n                    is a known risk factor for VL rebound with CAB\/RPV failures; thus, RPV therapeutic drug monitoring (TDM) was followed with regularly scheduled VL assessments. Based on TDM concentrations, monthly dose titration from standard CAB\/RPV 400\u2009mg\/600\u2009mg to 600\u2009mg\/900\u2009mg increased trough concentrations with VL suppression (&lt;200 copies mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    ) maintained. TDM may be an additional tool in this population with high BMI values to optimize CAB\/RPV dosing strategies as data accumulate in this high\u2010risk group for viral rebound with LA\u2010I therapy.\n                  <\/jats:p>","DOI":"10.1002\/bcp.70732","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:56:53Z","timestamp":1786327013000},"page":"3687-3690","source":"Crossref","is-referenced-by-count":0,"title":["Managing HIV in the extreme: Viral load and drug monitoring in a patient with BMI\u2009&gt;\u200960 on long\u2010acting cabotegravir\/rilpivirine therapy"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9853-1315","authenticated-orcid":false,"given":"Leah D.","family":"Baker","sequence":"first","affiliation":[{"name":"PGY2 Internal Medicine Pharmacy Resident Virginia Commonwealth University Health  Richmond Virginia USA"},{"name":"Clinical Pharmacist, Adult Floors and ICU WakeMed Health and Hospitals  Raleigh NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Pecora","family":"Fulco","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Specialist in Internal Medicine\/HIV, Department of Pharmacy Virginia Commonwealth University Health  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24543"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2985"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad580"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae579"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100793"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002883"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010\u2010025\u201002577\u2010x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf385"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf386"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae023"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14977"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae569"},{"key":"e_1_2_6_14_1","unstructured":"Cabenuva (cabotegravir extended\u2010release injectable suspension; rilpivirine extended\u2010release suspension) [FDA drug label]. Durham NC: ViiV Healthcare;2024."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf425"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae125"},{"key":"e_1_2_6_17_1","unstructured":"University of Liverpool.HIV drug interaction checker.http:\/\/www.hiv-druginteractions.org. Accessed January 26 2026"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2024.0083"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","unstructured":"SpinelliM HeiseMJ GliddenDV et al.Virologic outcomes after LA ART initiation with or without viremia in 2 large US clinic cohorts. Poster 529. Conference on Retroviruses and Opportunistic Infections2026Denver CO. Feb 22\u201325.","DOI":"10.1093\/cid\/ciag392"},{"key":"e_1_2_6_20_1","unstructured":"SensionM HsuRK FuscoJS et al.Body mass index and virologic outcomes in individuals on CAB + RPV LA in the OPERA cohort. Poster 534. Conference on Retroviruses and Opportunistic Infections2026Denver CO. Feb 22\u201325."},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004310"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2508228"},{"key":"e_1_2_6_23_1","unstructured":"RolleC\u2010P HoveK CahnP et al.Early switch to CAB + RPV LA in treatment\u2010na\u00efve adults with HIV\u20101: month 11 outcomes from VOLITION. Poster 525. Conference on Retroviruses and Opportunistic Infections2026Denver CO. Feb 22\u201325."},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103018(25)00131\u20106"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70732","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70732","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:55:55Z","timestamp":1790618155000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,9]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/bcp.70732"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70732","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,9]]}}}